NEW YORK, December 6, 2016 /PRNewswire/ --
Today, Stock-Callers.com navigates the Biotech arena to review the most recent performances of Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Amgen Inc. (NASDAQ: AMGN). According to IBISWorld's Global Biotechnology market research report released in May 2016, the industry is expected to continue prospering over the next five years, with the Asia/Pacific region making significant investments to gain a foothold in the market. Register now and get full and free access to our downloadable research reports on these stocks at:
New Jersey headquartered Celgene Corp.'s stock finished Monday's session 0.91% lower at $116.56. A total volume of 5.11 million shares was traded, which was above their three months average volume of 4.57 million shares. The Company's shares have advanced 13.88% in the past month and 9.23% in the previous three months. The stock is trading 7.01% above its 50-day moving average and 10.01% above its 200-day moving average. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have a Relative Strength Index (RSI) of 51.78.
On November 09th, 2016, research firm Standpoint Research downgraded the Company's stock rating from 'Buy' to 'Hold'.
On December 05th, 2016, Celgene announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) who had received prior hypomethylating agents (HMA). For all patients treated with CC-486, the overall response rate (ORR), which included complete remission (CR), partial remission (PR), CR with incomplete hematologic recovery (CRi; AML patients only), hematologic improvement (HI), and transfusion independence (TI), was 38%. Marrow CR (mCR) was assessed in MDS pts with ≥5% bone marrow blasts at baseline. Access our complete research report on CELG for free at:
On Monday, shares in Massachusetts headquartered Sarepta Therapeutics Inc. recorded a trading volume of 2.36 million shares. The stock ended the session 4.41% higher at $34.10. The Company's shares have advanced 22.71% in the previous three months. The stock is 23.66% above its 200-day moving average. Moreover, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, have an RSI of 32.68.
On November 30th, 2016, Sarepta Therapeutics granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven individuals hired by Sarepta in November 2016. The employees received, in the aggregate, options to purchase 22,875 shares of Sarepta's common stock. The options have an exercise price of $34.26 per share, equal to the Company's closing price on November 30th, 2016. The complimentary research report on SRPT can be downloaded at:
Shares in Valencia, California headquartered MannKind Corp. closed the day 5.89% higher at $0.58. The stock recorded a trading volume of 3.24 million shares. The Company's shares have gained 38.70% in the last month. The stock is trading 5.91% above its 50-day moving average. Additionally, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the US, have an RSI of 54.24.
On November 09th, 2016, MannKind announced that the promissory note and security agreement between MannKind and Aventisub LLC, a Sanofi affiliate, are terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $71.56 million. MannKind is also relieved from its obligation to pay $0.5 million in previously uncharged costs related to the collaboration. Sanofi will purchase $10.2 million worth of insulin from MannKind in early December as part of its pre-existing commitment to purchase insulin following termination of the collaboration and MannKind's exercise of a "put" option. Register for free on Stock-Callers.com and get access to the latest PDF format report on MNKD at:
At the close, shares in Thousand Oaks, California headquartered Amgen Inc. finished 0.89% higher at $145.29. The stock recorded a trading volume of 3.85 million shares, which was above its three months average volume of 3.76 million shares. The Company's shares have advanced 8.17% in the last one month. The stock is trading below its 50-day moving average by 5.44%. Furthermore, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have an RSI of 45.21.
On November 08th, 2016, research firm Mizuho initiated a 'Buy' rating on the Company's stock, issuing a target price of $164 per share.
On December 02nd, 2016, Amgen and Allergan PLC announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA. Download your free research report on AMGN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA